APA

Racioppi M., Di Gianfrancesco L., Ragonese M., Palermo G., Sacco E. & Bassi P. F. (20190325). ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. : BMC cancer.

Chicago

Racioppi Marco, Di Gianfrancesco Luca, Ragonese Mauro, Palermo Giuseppe, Sacco Emilio and Bassi Pier Francesco. 20190325. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. : BMC cancer.

Harvard

Racioppi M., Di Gianfrancesco L., Ragonese M., Palermo G., Sacco E. and Bassi P. F. (20190325). ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. : BMC cancer.

MLA

Racioppi Marco, Di Gianfrancesco Luca, Ragonese Mauro, Palermo Giuseppe, Sacco Emilio and Bassi Pier Francesco. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. : BMC cancer. 20190325.